Published online before print May 28, 2002, doi: 10.1161/01.CIR.0000019905.18467.07
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2981.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting
From the Cardiovascular Division, Department of Medicine, University of Calgary, Alberta, and Cardiovascular Division (M.M.G.), Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Correspondence to Todd J. Anderson, MD, Foothills Hospital, 1403 29th St NW, Calgary, AB, Canada T2N-2T9. E-mail todd.anderson{at}calgaryhealthregion.ca
Background— Platelet glycoprotein IIb/IIIa receptor blockade with abciximab decreases ischemic events after percutaneous coronary intervention (PCI); however, the mechanism of this benefit has not been fully elucidated. The present study was designed to assess endothelium-dependent vasomotion after coronary stenting and to determine if abciximab alters this response.
Methods and Results— The study group consisted of 48 patients (59±10 years of age) with discrete coronary stenoses who underwent stenting alone (n=28) or stenting plus abciximab (n=20). A control group consisted of 31 additional patients who had vasomotor testing on a non-PCI vessel. Coronary blood flow (CBF) was measured (0.014-inch Doppler wire) 30 minutes after uncomplicated PCI and in response to the intracoronary infusion of acetylcholine (Ach) (10-7, 10-6 mol/L Ach) and adenosine (24 µg). Ach-mediated increase in CBF was impaired after stent insertion when compared with the control group (41±52% versus 70±48%; P<0.05). The stenting plus abciximab group demonstrated a superior CBF response to Ach compared with the stenting alone group (83±93% versus 41±52%; P<0.05), with no difference between groups in the peak flow or percent change in flow to adenosine. By multivariate analysis, concomitant administration of abciximab was strongly predictive of the change in CBF to Ach (P<0.005).
Conclusions— Abciximab preserves the CBF response to Ach after coronary stenting. The preservation of microvascular endothelial function may help explain the beneficial clinical effect of this agent in patients undergoing PCI.
Key Words: angioplasty • endothelium • nitric oxide • glycoproteins
This article has been cited by other articles:
 |
|
 |
|
  S. S. Patel, H. Rana, and D. A. N. Mascarenhas Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 89 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 M. I. Worthley, R. S. Kanani, Y.-H. Sun, Y. Sun, D. M. Goodhart, M. J. Curtis, and T. J. Anderson Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries Cardiovasc Res, December 1, 2007; 76(3): 539 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1517 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lerman, D. R. Holmes, J. Herrmann, and B. J. Gersh Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? Eur. Heart J., April 1, 2007; 28(7): 788 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y-J Yang, J-L Zhao, S-J You, Y-J Wu, Z-C Jing, W-X Yang, L Meng, Y-W Wang, and R-L Gao Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion Heart, August 1, 2006; 92(8): 1131 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, R. Makkar, and J. Lardizabal Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 136 - 141. [Abstract] [PDF]
|
|
|
|
|
|
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dorffler-Melly, F. Mahler, D.-D. Do, J. Triller, and I. Baumgartner Adjunctive Abciximab Improves Patency and Functional Outcome in Endovascular Treatment of Femoropopliteal Occlusions: Initial Experience Radiology, December 1, 2005; 237(3): 1103 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Chaitman and M. J. Lim No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction J. Am. Coll. Cardiol., July 21, 2004; 44(2): 313 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Verma, M. R. Buchanan, and T. J. Anderson Endothelial Function Testing as a Biomarker of Vascular Disease Circulation, October 28, 2003; 108(17): 2054 - 2059. [Full Text] [PDF]
|
|
|
|
|
|
T. Heitzer, I. Ollmann, K. Koke, T. Meinertz, and T. Munzel Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease Circulation, August 5, 2003; 108(5): 536 - 541. [Abstract] [Full Text] [PDF]
|
|